Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The majority of patients with HCC are diagnosed at advanced disease stages with vascular invasion, where curative approaches are often not feasible. Currently, sorafenib is the only available standard therapy for HCC with portal vein tumor thrombosis (PVTT). However, in many cases, sorafenib therapy fails to achieve satisfactory results in clinical practice. We present a case of advanced HCC with PVTT that was treated with hepatic arterial infusion chemotherapy (HAIC) followed by liver transplantation. Three cycles of HAIC treatment resulted in necrotic changes in most of the tumors, and PVTT was reduced to an extent at which liver transplantation was possible. Further studies are required to determine the treatment strategies for advanced HCC with PVTT that can improve prognosis.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second most frequent cause of cancerrelated death worldwide. 1 Unlike other malignancies, the incidence and mortality rates of HCC will continue to increase over the next 20 years in some countries. 2 Portal vein tumor thrombosis (PVTT) is commonly accomaccompanied by advanced HCC. A substantial proportion of patients with HCC present with PVTT either at the onset of disease or as a result of HCC recurrence or progression, and their prognosis tends to be poor. Sorafenib has been proven to be the standard therapy for HCC with PVTT, according to most guidelines. 1, [3] [4] [5] However, the survival benefits of sorafenib administration are limited for patients from the Asia Pacific region. 6, 7 Some previous studies have reported favorable results associated with the application of hepatic arterial infusion chemotherapy (HAIC) in advanced HCC. [8] [9] [10] [11] Therefore, we report a case of liver transplantation after successful downstaging with HAIC in a patient with HCC and PVTT.
CASE REPORT
A Owing to these limitations of sorafenib, the requirement for alternative therapies has been increasing.
Of the various treatments for advanced HCC with PVTT, HAIC can be an alternative treatment option. HAIC has been applied to treat patients with advanced HCC that was unresectable, the infiltrative type, or in those with PVTT.
Theoretically, HAIC shows better efficacy than systemic cytotoxic chemotherapy, because the infusion of the chemotherapeutic agents through the hepatic artery enables direct delivery of high concentrations of drugs to the feeding arteries of the HCC. After selection of the tumor feeding artery, the catheter is inserted at the proper hepatic or common hepatic artery and connected to the port system. The port device in a subcutaneous pocket is implanted in the right or left iliac fossa. HAIC also minimizes systemic toxicities through a greater first-pass effect in the liver, reflecting lower systemic levels of the drugs compared to that in systemic infusion.
HAIC has been applied for advanced-stage HCC to improve the therapeutic indices in Asia, especially in Japan and Korea.
Song et al. 10 determined that the disease control rate of the HAIC group was higher than that of the sorafenib group (P <0.001), and that the OS (7.1 vs. 5.5 months, P =0.011) and time to progression (TTP) (P =0.034) were also significantly longer in the HAIC group. Further, according to the results of a recent randomized clinical trial, the HAIC group achieved better OS and TTP than the sorafenib group did (P =0.012 and P =0.010, respectively). In multivariate cox proportional hazard regression models, HAIC appeared to result in a better survival rate than that observed with sorafenib (P =0.005). 8 In addition, HAIC resulted in improved survival compared to that observed with sorafenib in patients with Vp3 or Vp4 PVTT. 18 Moreover, in patients with Vp3 or Vp4 PVTT, HAIC with concurrent irradiation for PVTT was more effective than HAIC alone. 9 The optimal regimen for HAIC in the treatment of HCC
has not yet been established, and a combination of cisplatin have been highly considered to overcome drug resistance and reduce toxicity. 19 Generally, the treatment cycles are repeated every 4 weeks until disease progression, unacceptable toxicity, or patient refusal to continue.
HAIC is known to have a favorable toxicity profile in patients with advanced HCC. The overall incidence of serious adverse events was significantly higher in the sorafenib group (20.7%) than in the HAIC group (6.9%). 8 In addition, discontinuation owing to adverse events was significantly more frequent in the sorafenib group than in the HAIC group. 18 
